series-a
Stage
2023
Founded
1
Investors
About
Radionetics Oncology develops small-molecule radiopharmaceuticals that target G-protein-coupled receptors over-expressed on cancer cells to deliver radioisotopes for diagnostic imaging and radiotherapy.
Explore Radionetics Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.